CYNBIOME™ : 1st excellence network on microbiota and infectious diseases
Based on the preclinical needs of academic research teams and biopharmaceutical companies, Cynbiose launches CYNBIOME™, the first excellence network on microbiota and infectious diseases based on the Non-Human Primate (NHP) model.
This new project aims to drive and structure the CYNBIOME™ excellence network. It will take full advantage of the synergy between local stakeholders by creating a division for the preclinical investigation of the microbiome.
“We would like to make the CYNBIOME™ structure a unique network that connects a translational model with technological tools, scientific and industrial expertise, and specialized partners for the preclinical study of microbiota in NHP models. This innovative project, the first of its kind in Europe, demonstrates Cynbiose’s ability to position itself as a spearhead in these major scientific and economic challenges, bringing together talents in a therapeutic field that addresses important public health needs,” said Hugues Contamin, CEO of Cynbiose. “The already available preclinical services will be continuously improved and complemented thanks to CYNBIOME™ R&D results. The project may also open up to other fields, such as metabolic, inflammatory and central nervous system diseases, at some point in the future.”
Overview of our preclinical services in the field of microbiome and infectious diseases, centered on the use of the NHP model. These services are aimed at the biopharmaceutical industry and will initially cover the preclinical validation of the safety of Live Biotherapeutic Products (LBPs), followed by studies on microbiota as a biomarker of, or natural adjuvant, to anti-infective agents. These services will subsequently be extended to other therapeutic areas.